Historique
Auteur T. P. FREEMAN
Documents disponibles écrits par cet auteur (21)
Ajouter le résultat à votre sélection Affiner la recherche
K. PETRILLI ; S. OFORI ; L. HINES ; G. TAYLOR ; S. ADAMS ; T. P. FREEMAN | 2022
Dans Lancet Psychiatry (The) (Vol.9, n°9, September 2022) Article : PériodiqueCannabis potency, defined as the concentration of Delta9-tetrahydrocannabinol (THC), has increased internationally, which could increase the risk of adverse health outcomes for cannabis users. We present, to our knowledge, the first systematic r[...]
C. HINDOCHA ; N. D. C. SHABAN ; T. P. FREEMAN ; R. K. DAS ; G. GALE ; G. SCHAFER ; C. J. FALCONER ; C. J. A. MORGAN ; H. V. CURRAN | 2015
Dans Drug and Alcohol Dependence (Vol.148, March 2015) Article : PériodiqueAims: To determine the degree to which cigarette smoking predicts levels of cannabis dependence above and beyond cannabis use itself, concurrently and in an exploratory four-year follow-up, and to investigate whether cigarette smoking mediates t[...]![Cannabis research in context: The case for measuring and embracing regional similarities and differences [Editorial]](https://bdoc.ofdt.fr/img_cache/pmb_ofdt_record_87271.webp)
J. COUSIJN ; L. KUHNS ; F. FILBEY ; T. P. FREEMAN ; E. KROON | 2024
Dans Addiction (Vol.119, n°9, September 2024) Article : PériodiqueConsiderable differences in the types of cannabis products, methods of use, social norms and cultures and legal climates surrounding use exist among regions, resulting in distinct cannabis use contexts. Research examining and accounting for thes[...]
T. P. FREEMAN ; S. CRAFT ; J. WILSON ; S. STYLIANOU ; M. ELSOHLY ; M. DI FORTI ; M. T. LYNSKEY | 2021
Dans Addiction (Vol.116, n°5, May 2021) Article : PériodiqueBACKGROUND AND AIMS: Cannabis products with high delta-9-tetrahydrocannabinol (THC) concentrations carry an increased risk of addiction and mental health disorders, while it has been suggested that cannabidiol (CBD) may moderate the effects of T[...]
K. R. THOMSEN ; C. LINDHOLST ; B. THYLSTRUP ; S. KVAMME ; L. A. REITZEL ; M. WORM-LEONHARD ; A. ENGLUND ; T. P. FREEMAN ; M. HESSE | 2019
Dans Experimental and Clinical Psychopharmacology (Vol.27, n°4, August 2019) Article : PériodiqueGlobally, recent studies report increases in Delta-9-tetrahydrocannabinol (THC) concentration in seized samples of cannabis for human consumption. This is important, because use of cannabis with a high concentration of THC has been linked to a n[...]
T. P. FREEMAN ; C. J. A. MORGAN ; J. VAUGHN-JONES ; N. HUSSAIN ; K. KARIMI ; H. V. CURRAN | 2012
Dans Addiction (Vol.107, n°4, April 2012) Article : PériodiqueAims - Use of the stimulant drug mephedrone increased dramatically in 2009, and it is still available in the United Kingdom after being controlled in April 2010. This study aimed to assess mephedrone's acute cognitive and subjective effects. De[...]![Controlling new drugs under marketing regulations [For debate]](https://bdoc.ofdt.fr/thumbnail.php?type=1&id=70863)
B. HUGHES, Auteur ; A. R. WINSTOCK, Auteur ; K. KRAJEWSKI, Auteur du commentaire ; J. SHERIDAN, Auteur du commentaire ; B. ATMORE, Auteur du commentaire ; B. RUSSELL, Auteur du commentaire ; P. REUTER, Auteur du commentaire ; T. P. FREEMAN, Auteur du commentaire ; H. V. CURRAN, Auteur du commentaire | 2012
Dans Addiction (Vol.107, n°11, November 2012) Article : PériodiqueAims: The rapid emergence of myriad substances openly marketed as ‘legal highs’ is straining traditional drug control systems which require time and basic scientific data on harms to react, presenting governments with the dilemma of no response [...]Nouveauté
S. CRAFT ; P. SUNDERLAND ; M. F. MILLEA ; C. R. PUDNEY ; O. B. SUTCLIFFE ; T. P. FREEMAN | 2025
Dans Addiction (Vol.120, n°3, March 2025) Article : PériodiqueBACKGROUND AND AIMS: In the United Kingdom and internationally, synthetic cannabinoids (SCs) are a common adulterant in illicitly sourced vaping products. Recently, their use is increasingly being linked to severe health effects, particularly am[...]
M. GRABSKI ; J. WALDRON ; T. P. FREEMAN ; C. MOKRYSZ ; R. J. J. VAN BEEK ; P. VAN DER POL ; B. HAUSPIE ; N. DIRKX ; J. SCHROOTEN ; T. H. ELGAN ; K. FELTMAN ; E. BENEDETTI ; G. SCALIA TOMBA ; F. FABI ; S. MOLINARO ; J. GRIPENBERG ; T. VAN HAVERE ; M. VAN LAAR ; H. V. CURRAN | 2022
Dans European Addiction Research (Vol.28, n°2, March 2022) Article : PériodiqueBACKGROUND: Monitoring emerging trends in the increasingly dynamic European drug market is vital; however, information on change at the individual level is scarce. In the current study, we investigated changes in drug use over 12 months in Europ[...]
K. PETRILLI ; W. LAWN ; R. LEES ; C. MOKRYSZ ; A. BORISSOVA ; S. OFORI ; K. TRINCI ; R. DOS SANTOS ; H. LEITCH ; S. SONI ; L. A. HINES ; V. LORENZETTI ; H. V. CURRAN ; T. P. FREEMAN | 2024
Dans Addiction (Vol.119, n°4, April 2024) Article : PériodiqueAIMS: The aims of this study were to present an enhanced cannabis timeline followback (EC-TLFB) enabling comprehensive assessment of cannabis use measures, including standard tetrahydrocannabinol (THC) units, and to validate these against object[...]
T. P. FREEMAN ; A. R. WINSTOCK | 2015
Dans Psychological Medicine (Vol.45, n°15, November 2015) Article : PériodiqueBackground. Cannabis use is decreasing in England and Wales, while demand for cannabis treatment in addiction services continues to rise. This could be partly due to an increased availability of high-potency cannabis. Method. Adults residing in[...]
A. AUSTIN ; L. FAVRIL ; S. CRAFT ; P. THLIVERI ; T. P. FREEMAN | 2023
Dans International Journal of Drug Policy (Vol.122, December 2023) Article : PériodiqueBackground: About a third of people use drugs during their incarceration, which is associated with multiple adverse health and criminal justice outcomes. Many studies have examined factors associated with in-prison drug use, but this evidence ha[...]
T. P. FREEMAN ; T. GROSHKOVA ; A. CUNNINGHAM ; R. SEDEFOV ; P. GRIFFITHS ; M. T. LYNSKEY | 2019
Dans Addiction (Vol.114, n°6, June 2019) Article : PériodiqueENGLISH: AIMS: To quantify changes in (i) potency (concentration of Delta9-tetrahydrocannabinol; %THC), (ii) price (euros/g of cannabis) and (iii) value (mg THC/euro) of cannabis resin and herbal cannabis in Europe. DESIGN: Repeated cross-sect[...]
T. P. FREEMAN ; C. HINDOCHA ; S. F. GREEN ; M. A. P. BLOOMFIELD | 2019
Dans British Medical Journal (Vol.365, n°8194, 6 April 2019) Article : PériodiqueWhat you need to know: Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including Delta9-tetrahydrocananbinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for m[...]
S. CHANDRA ; M. M. RADWAN ; C. G. MAJUMDAR ; J. C. CHURCH ; T. P. FREEMAN ; M. A. ElSOHLY | 2019
Dans European Archives of Psychiatry and Clinical Neuroscience (Vol.269, n°1, February 2019) Article : PériodiqueENGLISH: Through the potency monitoring program at the University of Mississippi supported by National Institute on Drug Abuse (NIDA), a total of 18108 samples of cannabis preparations have been analyzed over the last decade, using a validated [...]
